Longevity & Aging
partial reprogramming (OSK) mitigates age-related vision loss
In plain terms: Can gene "reprogramming" reverse age-related vision loss?
Part of: 🩺 partial reprogramming (osk)
Yes, it restored sight after injury and ageing, but only shown in mice so far, with no human data.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
How the studies fall
What the evidence shows
OSK (Myc omitted to limit cancer risk) regenerates optic-nerve axons and restores vision after injury/glaucoma/aging in MICE via TET-dependent demethylation (Lu-Sinclair 2020). Striking but species- and tissue-limited; no human data.
The evidence (13)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Paine 2023 · Front Aging | animal | tested-null | moderate | Independent lab: initiation-phase in vivo reprogramming ameliorated DNA damage in ERCC1 progeroid mice, supporting OSK partial-reprogramming rejuvenation mechanism (non-ocular). |
| Yang JH 2023 · Aging (Albany) | in-vitro | mixed | low | Chemically-induced OSK-based reprogramming reversed cellular-aging markers (DNA methylation, transcriptome) without loss of identity - mechanistic basis for the OSK vision work (same lab). |
| Zhang K 2024 · Invest Ophthalmol Vis Sci | in-vitro | tested-null | low | Reprogramming-based induced retinal ganglion cell model: Shootin1 regulates RGC neurite/axon development, supporting reprogramming as a route to regenerate vision-relevant RGCs. |
| Paine PT 2024 · Aging Cell | animal | supports | moderate | Review of partial reprogramming: real rejuvenation signal across models but unresolved tumour/safety risk and no human efficacy data - tempers the vision claim. |
| Yang 2023 · Cell | animal | supports | low | [FT-verified] ICE/Cell2023 same Sinclair lab reaffirms; reinforces not independent. ANIMAL-ONLY ⚠️ correction-on-file (Crossref) - kept, corrigendum not retraction |
| Karg MM 2023 · Cell Reprogram | animal | supports | moderate | OSK gene therapy in a mouse glaucoma model: 2 months of OSK expression fully restored vision, sustained 11 months during continuous expression and persisting above baseline after withdrawal; no adverse effects over 21 months. Direct in-vivo evidence OSK reprogramming reverses vision loss (mouse-only). |
| Jo BK 2025 · Aging Cell | animal | supports | low | Review of in vivo reprogramming: promising organ-specific dedifferentiation but persistent safety/clinical-applicability concerns; vision restoration remains preclinical. |
| Lu 2020 · Nature | animal | supports | moderate | [FT-verified] Lu-Sinclair Nature2020 MOUSE RGC OSK restores vision via TET demethylation. ANIMAL-ONLY species caveat |
| Zhang K 2026 · Stem Cell Reports | in-vitro | mixed | low | Mettl3/m6A promotes reprogramming and axonogenesis of induced retinal ganglion cells - mechanistic support for reprogramming-driven RGC regeneration. |
| Nakatsukasa 2025 · Regen Ther | animal | supports | low | [FT-verified] Yamada review in-vivo partial reprogramming citing restored vision. ANIMAL/MECHANISM-ONLY |
| Nunez-Quintela 2026 · Trends Mol Med | mechanism | supports | moderate | [FT-verified] Collado review partial reprogramming rejuvenates tissue/regen capacity. ANIMAL/MECHANISM-ONLY |
| Alle Q 2022 · Aging Cell | animal | tested-null | low | Independent lab: a single short in vivo OSKM reprogramming pulse improved tissue function and healthspan in mice, supporting OSK rejuvenation generality (non-ocular). |
| Schoenfeldt L 2025 · EMBO Mol Med | animal | tested-null | low | Independent lab: chemical (OSK-mimetic) reprogramming ameliorated aging hallmarks and extended lifespan in mice - corroborates reprogramming-rejuvenation mechanism (non-ocular). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.